Metabolon Appoints Andrew Messick as Chief Financial Officer (metabolon.com)

• Andrew Messick appointed CFO of Metabolon, effective February 3, 2026.
• Messick has over 25 years of life sciences finance experience, including M&A.
• CEO Rohan Hastie cited Messick’s expertise in scaling and strategic execution.

"Metabolon, Inc. announced the appointment of Andrew (Drew) Messick as Chief Financial Officer, effective February 3, 2026. Messick brings over 25 years of financial leadership in life sciences, with experience in M&A and operational excellence. He will support Metabolon's scaling and strategic objectives under CEO Rohan Hastie. The appointment strengthens Metabolon's executive team as it expands capabilities and market presence."